These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 16166607)
41. Medicine. What are the right targets for psychopharmacology? Hyman SE; Fenton WS Science; 2003 Jan; 299(5605):350-1. PubMed ID: 12532001 [No Abstract] [Full Text] [Related]
42. Ethical issues in the NIMH Collaborative HIV/STD Prevention Trial. NIMH Collaborative HIV/STD Prevention Trial Group AIDS; 2007 Apr; 21 Suppl 2():S69-80. PubMed ID: 17413266 [TBL] [Abstract][Full Text] [Related]
47. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738 [TBL] [Abstract][Full Text] [Related]
48. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Insel TR Arch Gen Psychiatry; 2009 Feb; 66(2):128-33. PubMed ID: 19188534 [TBL] [Abstract][Full Text] [Related]
49. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076 [TBL] [Abstract][Full Text] [Related]
50. The NIMH-MATRICS consensus statement on negative symptoms. Kirkpatrick B; Fenton WS; Carpenter WT; Marder SR Schizophr Bull; 2006 Apr; 32(2):214-9. PubMed ID: 16481659 [No Abstract] [Full Text] [Related]
51. [Correlation between cognitive defects and the course of schizophrenia. Initial study of a rehabilitation programme participants]. Hanuszkiewicz I; Cechnicki A; Kalisz A Psychiatr Pol; 2007; 41(4):539-50. PubMed ID: 18046984 [TBL] [Abstract][Full Text] [Related]
52. Methods for treating cognitive deficits in schizophrenia. Bowie CR; Jaga K Expert Rev Neurother; 2007 Mar; 7(3):281-7. PubMed ID: 17341176 [TBL] [Abstract][Full Text] [Related]
53. Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. Fenton WS; Stover EL; Insel TR Psychopharmacology (Berl); 2003 Sep; 169(3-4):365-6. PubMed ID: 12955292 [No Abstract] [Full Text] [Related]
54. Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia. Roffman JL; Weiss AP; Goff DC; Rauch SL; Weinberger DR Harv Rev Psychiatry; 2006; 14(2):78-91. PubMed ID: 16603474 [TBL] [Abstract][Full Text] [Related]
55. New approaches to measurement and treatment research to improve cognition in schizophrenia. Geyer MA; Heinssen R Schizophr Bull; 2005 Oct; 31(4):806-9. PubMed ID: 16166608 [TBL] [Abstract][Full Text] [Related]
56. National Institute of Mental Health Support for Cognitive Treatment Development in Schizophrenia: A Narrative Review. Heinssen RK; Morris SE; Sherrill JT Schizophr Bull; 2024 Jun; ():. PubMed ID: 38941445 [TBL] [Abstract][Full Text] [Related]
57. The MATRICS Consensus Cognitive Battery: An Update. Nuechterlein KH; Green MF; Kern RS Curr Top Behav Neurosci; 2023; 63():1-18. PubMed ID: 36306054 [TBL] [Abstract][Full Text] [Related]
58. Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers. Tcheremissine OV; Castro MA; Gardner DR Expert Opin Investig Drugs; 2012 Jan; 21(1):7-14. PubMed ID: 22059602 [TBL] [Abstract][Full Text] [Related]
59. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. Marder SR J Clin Psychiatry; 2006 Jul; 67(7):e03. PubMed ID: 17107228 [TBL] [Abstract][Full Text] [Related]
60. NIMH report. An interview with Lewis Judd, M.D.. Interview by Marilyn Sargent. Judd L Hosp Community Psychiatry; 1988 May; 39(5):493-4, 500. PubMed ID: 2837426 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]